Previous 10 | Next 10 |
FLORHAM PARK, N.J., June 05, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq: CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the closing of its previously announced un...
Gainers: Genius Brands International (NASDAQ: GNUS ) +73% . More news on: Genius Brands International, Inc., Cassava Sciences, Inc., Secoo Holding Limited, Stocks on the move, , Read more ...
Cellectar Biosciences (NASDAQ: CLRB ) has priced its public offering for gross proceeds of $20M. More news on: Cellectar Biosciences, Inc., Healthcare stocks news, , Stocks on the move, Read more ...
Evofem Biosciences (NASDAQ: EVFM ) -26% after pricing equity offering. More news on: Evofem Biosciences, Inc., Cellectar Biosciences, Inc., Reinsurance Group of America, Incorporated, Stocks on the move, , Read more ...
FLORHAM PARK, N.J., June 03, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the pricing of an underwritten ...
FLORHAM PARK, N.J., June 01, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that it has been granted Small ...
La Jolla Pharmaceutical (NASDAQ: LJPC ) -24% . More news on: La Jolla Pharmaceutical Company, Arcus Biosciences, Inc., Mitcham Industries, Inc., Stocks on the move, , Read more ...
Mmtec (NASDAQ: MTC ) +168% on FY results . More news on: Mmtec, Inc., Sky Solar Holdings, Ltd., Cellectar Biosciences, Inc., Stocks on the move, , Read more ...
The FDA grants Fast Track status to Cellectar Biosciences (NASDAQ: CLRB ) CLR 131 application for patients with lymphoplasmacytic lymphoma (LPL)/ Waldenstrom’s macroglobulinemia (WM) in patients who have received at least two prior lines of therapy. More news on: Cellectar Biosci...
FLORHAM PARK, N.J., May 26, 2020 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced the U.S. Food and Drug Administration...
News, Short Squeeze, Breakout and More Instantly...
Cellectar Biosciences Inc. Company Name:
CLRB Stock Symbol:
NASDAQ Market:
Cellectar Biosciences Inc. Website:
56.4% major response rate exceeded 20% primary endpoint 98.2% disease control rate achieved in heavily pretreated patients Responses shown in difficult-to-treat, high-needs patient populations with approximately 27% of patients refractory to all available therapies and 40%...
FLORHAM PARK, N.J., July 22, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced that the majority of Tranche B warran...
FLORHAM PARK, N.J., June 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announced it will host an event on July 24, 202...